BESPONSA is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).2

PP-INO-GBR-0122. May 2020


1. NICE Technology Appraisal Guidance (TA541). Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. Available at: Published: 19 September 2018. Accessed: March 2020.

2. BESPONSA® SmPC Summary of Marketing Product Characteristics


Prescribing information

BESPONSA® (inotuzumab ozogamicin) 1 mg powder for concentrate for solution for infusion

Legal category: Prescription only medicine. Cost: £8,048 per vial.

Click here to access the BESPONSA Summary of Product Characteristics hosted on Datapharm’s ‘electronic Medicines Compendium’.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

Cytarabine 20 mg/mL and 100 mg/mL solution for infusion or injection

Legal category: Prescription only medicine. Basic NHS price: Cytarabine 100 mg/mL, supplied as single vials containing 100 mg/mL cytarabine in 10 mL (1 g), £39.00 or 20 mL (2 g), £77.50. Cytarabine 20 mg/mL supplied as vials containing 20 mg/mL cytarabine in 5 mL (100 mg) in packs of 5, £20.48 or 25 mL (500 mg) as single vials, £19.50. 
Click here to access the cytarabine 20 mg/mL and click here to access the 100 mg/mL Summary of Product Characteristics hosted on Datapharm’s ‘electronic Medicines Compendium’.